News for hackers. Stuff that matters.
Re:Ben Goldacre: Here’s the foreword to my new book, Bad Pharma by refurb on Tuesday September 25, 2012 @12:29PM (#4571196)
Again, I'd have to disagree with you.

$8K of the $10K is not money used to grease the wheels to get studies done. Think about it: you're treating a patient for a whole year with a new drug. You're dosing the drug, taking blood samples, monitoring the patient closely, running tests to determine endpoints, collecting and processing data. You think that would only cost $2K/yr/pt?

Pharma companies may incentivize physicians to participate in clinical trials, but that $10K-$20K is the cost of running the actual trial. Doctors, physicians, technicians, data analysts don't come cheap.

And no, the majority of drug approval studies don't have only a couple hundred patients. If you're doing research for an orphan drug or an extremely rare cancer, that might be true, but those hardly make up a majority of the drug trials that happen.

A great example, Contrave an obesity drug went in front of the FDA. The FDA wanted more data (on top of the phase III studies that were already done). How many patients for the additional trial? 10,000.

There are no comments on this comment yet.